Current Research: Retatrutide is the first triple agonist peptide targeting the Glucagon, GLP-1, and GIP receptors.

• Retatrutide: It's a novel triple agonist that mimics three hormones: GLP-1, GIP, and glucagon. This combination promotes significant body size reduction, improves blood sugar control, and offers other metabolic benefits.
• Sermorelin: It's a growth hormone-releasing hormone (GHRH) analog. It stimulates the pituitary gland to release natural human growth hormone (hGH), potentially leading to increased muscle mass, improved sleep, and enhanced energy levels.

Among its predecessors, Liraglutide (Victoza, Saxenda), Exenatide (Byetta), Semaglutide (Ozempic, Rybelsus, Wegovy), Lixisenatide (Adlyxin), and Dulaglutide ( Trulicity) are GLP-1 receptor agonists, Tirzepatide (Mounjaro) is a GLP-1/GIP dual receptor co-agonist. Survodutide is a Glucagon/GLP-1 dual receptor co-agonist.

The offer is for 1 gram of Sermorelin and 1 gram of Retatrutide. Total size of 2 grams. Can be sent individually without blending them together.